Here are relevant reports on : oncology-diagnostics-market
-
Endoscopic Ultrasonography (EUS) Market by Product (Endoscopes, Ultrasound Processors, Ultrasound Needles, Probes), Type (Diagnostic, Therapeutic), Application (Oncology, GI, End User (Hospitals, Ambulatory Surgical Center) - Global Forecast to 2029
The global endoscopic ultrasonography market, valued at US$1.28 billion in 2023, stood at US$1.37 billion in 2024 and is projected to advance at a resilient CAGR of 7.1% from 2024 to 2029, culminating in a forecasted valuation of US$1.93 billion by the end of the period. The growth in the endoscopic ultrasonography market can be attributed to the factors, including increasing investments, funds, and grants by governments and other organizations, rising focus of hospitals to expand endoscopic ultrasonography units and bring advancements in endoscopic ultrasonography technologies.
- Published: February 2025
- Price: $ 4950
- TOC Available:
-
North America Epigenetics Market by Product & Service [Enzymes, Kits & Reagents (Antibodies), Software], Method [DNA Methylation, Histone Modification], Technique [NGS, PCR], Application [Oncology, Immunology, Developmental Biology]-Forecast to 2030
The North America epigenetics market, valued at USD 0.84 billion in 2024, stood at USD 0.93 billion in 2025 and is projected to advance at a resilient CAGR of 13.8% from 2025 to 2030, culminating in a forecasted valuation of USD 1.78 billion by the end of the period. Growth of the North America epigenetics market is driven by a strong, well-funded life sciences ecosystem, with rising oncology and precision-medicine programs that rely on methylation and chromatin profiling.
- Published: October 2026
- Price: $ 4950
- TOC Available:
-
Contrast Enhanced Ultrasound Market by Product (Equipment, Nanoparticle & Molecule-targeted Microbubbles, Software], Application (Diagnostic, Therapeutic, CVDs, Liver, Kidney, Oncology), End User (Hospital, Clinics, ASCs) & Region - Global Forecast to 2028
The global contrast enhanced ultrasound market, valued at US$1.4 billion in 2022, stood at US$1.6 billion in 2023 and is projected to advance at a resilient CAGR of 6.1% from 2023 to 2028, culminating in a forecasted valuation of US$2.1 billion by the end of the period. The rising use of contrast agents, increasing partnerships and collaborations, and the introduction of novel technologies are expected to drive the market during the forecast period.
- Published: August 2023
- Price: $ 4950
- TOC Available:
-
Biosimilars Market by Drug Class (mAbs [Adalimumab, Infliximab, Rituximab, Trastuzumab], GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2036
The global biosimilars market is projected to reach USD 70.79 billion by 2036, growing at a CAGR of 6.6% during the forecast period (2026–2036). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: September 2026
- Price: $ 4950
- TOC Available:
-
Active Pharmaceutical Ingredients (API) Market by Type (Innovative, Generic), Synthesis (Synthetic, Biotech), Potency (HPAPI), Product (mAbs, Hormones, Cytokines), Type of Drug (OTC, Rx), Application (Diabetes, Oncology), Competition - Global forecast to 2031
The global active pharmaceutical ingredients (API) market is projected to reach USD 199.42 billion by 2031, growing at a CAGR of 6.0% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: October 2026
- Price: $ 4950
- TOC Available:
-
Nuclear Imaging Equipment Market by Product (SPECT (Hybrid SPECT, Standalone SPECT), Hybrid PET, & Planar Scintigraphy), Application (Oncology, Cardiology & Neurology) & End user (Hospitals, Imaging Centers) & Region - Global Forecast to 2025
The global nuclear imaging equipment market growth is primed to transition from $2.6 billion in 2020 to $3.4 billion by 2025, showcasing a strong CAGR of 7.4%. The growth in this market is mainly driven by the the shift from standalone to hybrid modalities, advances in radiotracers, the increasing focus on personalized medicine, investments through public-private partnerships to modernize diagnostic imaging centers, and the increasing incidence and prevalence of cancer and cardiac ailments.
- Published: February 2021
- Price: $ 4950
- TOC Available:
-
Picture Archiving and Communications Systems/ PACS Systems Market– By Components (Software and Hardware), Delivery Mode & Imaging Types [Cardiology PACS, Oncology PACS, Dental PACS] - Global Trends, Competitor Analysis & Forecasts To 2017
PACS stands for picture archiving and communication system. PACS has helped in reducing the physical and time barriers associated with traditional film-based image retrieval, distribution, and display. PACS is finding widespread application in hospitals and clinics as it eliminates the need of maintaining hard copies of images and replaces them with digital storage. Market for PACS solutions is growing at a faster rate as healthcare providers are finding it difficult to remain competitive without PACS. Most of the players who are offering PACS to larger hospitals are now targeting small hospitals and diagnostic centers. The Global PACS market is estimated at $2.5 Billion in 2010 and is expected to grow at a CAGR of 14.9% and reach $5 Billion.
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
Clinical Trial Services Market by Type (Lab, Monitoring, Contracts, Recruitment, PV, Biostatistics), Phase (I, II, III), Therapy (Oncology, Neurology, Dermatology, CVD), Modality (Biologics, Devices), Delivery Model (FSP, Hybrid) - Global forecast to 2031
The global clinical trial services market is projected to reach USD 97.41 billion by 2031, growing at a CAGR of 8.0% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: September 2026
- Price: $ 4950
- TOC Available:
-
North America Injectable Drug Delivery Market – by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics [Diabetes & Oncology] – Forecasts to 2017
The North American injectable drug delivery technologies market was valued at $9.3 billion in 2012; it is expected to reach $16.6 billion by 2017 at a CAGR of 12.3% from 2012 to 2017. Injectable drug delivery technologies are the combination of two major segments; devices and formulations. The North American injectable drug delivery formulations technologies market was the largest segment in this market. In addition, the market is segmented on the basis of its therapeutic applications. In therapeutic area, hormonal disorders command the major segment of injectable drug delivery technologies market due to high demand of injectable in treatment of diabetes. However, auto-immune diseases are the fastest growing segment of this market due to the advent of biologics (tumor necrosis factor (TNF) and Interleukin 1 (IL-1)) and improving patient compliance by the development of self injection devices.
- Published: April 2013
- Price: $ 4950
- TOC Available:
-
Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017
The market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 80.7% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by thallium–201(Tl-201), gallium–67 (Ga-67), and iodine-123 (I-123). SPECT is majorly used in cardiology-related diagnosis; it is poised to grow at a CAGR of 10.2% from 2012 to 2017. The radiopharmaceuticals market in the Asia-Pacific region was valued at $500.8 million in 2012; it is poised to reach $824.9million in 2017 at a CAGR of 10.5%.
- Published: May 2013
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
